SCHEMBL30656182

SCHEMBL30656182

Cc1sc2ccc(OCc3ccccc3F)cc2c1C(=O)NC1(CO)COC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.40
PARP15 Q460N3 3/20 0.39
PARP10 Q53GL7 3/20 0.39
PARP14 Q460N5 1/20 0.37
MMP1 P03956 1/20 0.37
MMP13 P45452 1/20 0.37
CD274 Q9NZQ7 1/20 0.36
SLC26A4 O43511 1/20 0.36
SCN3A Q9NY46 2/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
CDC25B P30305 1/20 0.36
SCN9A Q15858 1/20 0.36
KCNH2 Q12809 2/20 0.35
RARA P10276 1/20 0.35
RARB P10826 1/20 0.35
RARG P13631 1/20 0.35
GCK P35557 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30656149 0.93 PARP15 (0.41) MAOBPARP15PARP10PARP14MMP1
SCHEMBL30656068 0.92 MMP13 (0.42) MAOBPARP15PARP10PARP14MMP1
SCHEMBL30656091 0.91 PARP15 (0.39) MAOBPARP15PARP10PARP14MMP1
SCHEMBL30656050 0.88 PARP15 (0.41) MAOBPARP15PARP10PARP14MMP1
SCHEMBL30656164 0.84 FGFR4 (0.41) KCNH2
SCHEMBL24470736 0.83 SLC26A4 (0.54) SLC26A4
SCHEMBL29713042 0.83 SLC26A4 (0.54) SLC26A4
SCHEMBL30656111 0.83 MMP1 (0.46) MAOBPARP15PARP10PARP14MMP1
SCHEMBL30656220 0.82 L3MBTL1 (0.33)
SCHEMBL31351337 0.80 PARP10 (0.48) MAOBPARP15PARP10PARP14SLC26A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US claimed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP claimed
CN-119421879-A Novel derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-02-11 CN claimed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO claimed
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US disclosed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
CN-119421879-A Novel derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-02-11 CN disclosed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 MAOB 2260/4885PARP15 1452/4885PARP10 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.